Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors

Journal of Biomolecular Screening

Volumn 18, Issue 4, 2013, Pages 388-399

  Ahmad, Syed ^a   Hughes, Mark A ^a   Johnson, Gary L ^b   Scott, John E ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ATPase; bosutinib; crizotinib; MAP3K2; MEKK2

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AXITINIB; BOSUTINIB; CRIZOTINIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2 INHIBITOR; NILOTINIB; PAZOPANIB; PROTEIN SERINE THREONINE KINASE INHIBITOR; SORAFENIB; STAUROSPORINE; SUNITINIB; TEMSIROLIMUS; TOFACITINIB; TOZASERTIB; UNCLASSIFIED DRUG; VANDETANIB;

ARTICLE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; IC 50; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATASES; DRUG DISCOVERY; ENZYME ASSAYS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE KINASE 2; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS;

EID: 84875715993     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112466430     Document Type: Article

References (30)

1. Whitmarsh A. J.. Regulation of Gene Transcription by Mitogen-Activated Protein Kinase Signaling Pathways. Biochim. Biophys. Acta. 2007 ; 1773: 1285-1298
2. Kim E. K., Choi E. J.. Pathological Roles of MAPK Signaling Pathways in Human Diseases. Biochim. Biophys. Acta. 2010 ; 1802: 396-405
3. Drew B. A., Burow M. E., Beckman B. S.. MEK5/ERK5 Pathway: The First Fifteen Years. Biochim. Biophys. Acta. 2012 ; 1825: 37-48
4. Yan L., Carr J., Ashby P. R., Murry-Tait V., Thompson C., Arthur J. S.. Knockout of ERK5 Causes Multiple Defects in Placental and Embryonic Development. BMC Dev. Biol. 2003 ; 3: 11
5. Wang X., Tournier C.. Regulation of Cellular Functions by the ERK5 Signalling Pathway. Cell Signal. 2006 ; 18: 753-760
6. Pi X., Yan C., Berk B. C.. Big Mitogen-Activated Protein Kinase (BMK1)/ERK5 Protects Endothelial Cells from Apoptosis. Circ. Res. 2004 ; 94: 362-369
7. Wang X., Merritt A. J., Seyfried J., Guo C., Papadakis E. S., Finegan K. G., Kayahara M., Dixon J., Boot-Handford R. P., Cartwright E. J., Mayer U., Tournier C.. Targeted Deletion of mek5 Causes Early Embryonic Death and Defects in the Extracellular Signal-Regulated Kinase 5/Myocyte Enhancer Factor 2 Cell Survival Pathway. Mol. Cell. Biol. 2005 ; 25: 336-345
8. Sun W., Kesavan K., Schaefer B. C., Garrington T. P., Ware M., Johnson N. L., Gelfand E. W., Johnson G. L.. MEKK2 Associates with the Adapter Protein Lad/RIBP and Regulates the MEK5-BMK1/ERK5 Pathway. J. Biol. Chem. 2001 ; 276: 5093-5100
9. Chao T. H., Hayashi M., Tapping R. I., Kato Y., Lee J. D.. MEKK3 Directly Regulates MEK5 Activity as Part of the Big Mitogen-Activated Protein Kinase 1 (BMK1) Signaling Pathway. J. Biol. Chem. 1999 ; 274: 36035-36038
10. Garrington T. P., Ishizuka T., Papst P. J., Chayama K., Webb S., Yujiri T., Sun W., Sather S., Russell D. M., Gibson S. B., Keller G., Gelfand E. W., Johnson G. L.. MEKK2 Gene Disruption Causes Loss of Cytokine Production in Response to IgE and c-Kit Ligand Stimulation of ES Cell-Derived Mast Cells. EMBO J. 2000 ; 19: 5387-5395
11. Guo Z., Clydesdale G., Cheng J., Kim K., Gan L., McConkey D. J., Ullrich S. E., Zhuang Y., Su B.. Disruption of Mekk2 in Mice Reveals an Unexpected Role for MEKK2 in Modulating T-cell Receptor Signal Transduction. Mol. Cell Biol. 2002 ; 22: 5761-5768
12. Yang J., Boerm M., McCarty M., Bucana C., Fidler I. J., Zhuang Y., Su B.. Mekk3 Is Essential for Early Embryonic Cardiovascular Development. Nat. Genet. 2000 ; 24: 309-313
13. Kesavan K., Lobel-Rice K., Sun W., Lapadat R., Webb S., Johnson G. L., Garrington T. P.. MEKK2 Regulates the Coordinate Activation of ERK5 and JNK in Response to FGF-2 in Fibroblasts. J. Cell Physiol. 2004 ; 199: 140-148
14. Cheng J., Yu L., Zhang D., Huang Q., Spencer D., Su B.. Dimerization through the Catalytic Domain Is Essential for MEKK2 Activation. J. Biol. Chem. 2005 ; 280: 13477-13482
15. Montero J. C., Ocana A., Abad M., Ortiz-Ruiz M. J., Pandiella A., Esparis-Ogando A.. Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies This Kinase as a Potential Therapeutic Target. PLoS One. 2009 ; 4: e5565
16. Cazares L. H., Troyer D., Mendrinos S., Lance R. A., Nyalwidhe J. O., Beydoun H. A., Clements M. A., Drake R. R., Semmes O. J.. Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue. Clin. Cancer Res. 2009 ; 15: 5541-5451
17. McCracken S. R., Ramsay A., Heer R., Mathers M. E., Jenkins B. L., Edwards J., Robson C. N., Marquez R., Cohen P., Leung H. Y.. Aberrant Expression of Extracellular Signal-Regulated Kinase 5 in Human Prostate Cancer. Oncogene. 2008 ; 27: 2978-2988
18. Carvajal-Vergara X., Tabera S., Montero J. C., Esparis-Ogando A., Lopez-Perez R., Mateo G., Gutierrez N., Parmo-Cabanas M., Teixido J., San Miguel J. F., Pandiella A.. Multifunctional Role of Erk5 in Multiple Myeloma. Blood. 2005 ; 105: 4492-4499
19. Clape C., Fritz V., Henriquet C., Apparailly F., Fernandez P. L., Iborra F., Avances C., Villalba M., Culine S., Fajas L.. miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice. PLoS One. 2009 ; 4: e7542
20. Sticht C., Freier K., Knopfle K., Flechtenmacher C., Pungs S., Hofele C., Hahn M., Joos S., Lichter P.. Activation of MAP Kinase Signaling through ERK5 but not ERK1 Expression Is Associated with Lymph Node Metastases in Oral Squamous Cell Carcinoma (OSCC). Neoplasia. 2008 ; 10: 462-470
21. Yang Q., Deng X., Lu B., Cameron M., Fearns C., Patricelli M. P., Yates J. R., Gray N. S., Lee J. D.. Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein. Cancer Cell. 2010 ; 18: 258-267
22. Mehta P. B., Jenkins B. L., McCarthy L., Thilak L., Robson C. N., Neal D. E., Leung H. Y.. MEK5 Overexpression Is Associated with Metastatic Prostate Cancer, and Stimulates Proliferation, MMP-9 Expression and Invasion. Oncogene. 2003 ; 22: 1381-1389
23. Cronan M. R., Nakamura K., Johnson N. L., Granger D. A., Cuevas B. D., Wang J. G., Mackman N., Scott J. E., Dohlman H. G., Johnson G. L.. Defining MAP3 Kinases Required for MDA-MB-231 Cell Tumor Growth and Metastasis. Oncogene. 2012 ; 31: 3889-3900
24. Fox T., Fitzgibbon M. J., Fleming M. A., Hsiao H. M., Brummel C. L., Su M. S.. Kinetic Mechanism and ATP-Binding Site Reactivity of p38gamma MAP Kinase. FEBS Lett. 1999 ; 461: 323-328
25. Rominger C. M., Schaber M. D., Yang J., Gontarek R. R., Weaver K. L., Broderick T., Carter L., Copeland R. A., May E.W.. An Intrinsic ATPase Activity of Phospho-MEK-1 Uncoupled from Downstream ERK Phosphorylation. Arch. Biochem. Biophys. 2007 ; 464: 130-137
26. Kashem M. A., Nelson R. M., Yingling J. D., Pullen S. S., Prokopowicz A. S., Jones J. W., Wolak J. P., Rogers G. R., Morelock M. M., Snow R. J., Homon C. A., Jakes S.. Three Mechanistically Distinct Kinase Assays Compared: Measurement of Intrinsic ATPase Activity Identified the Most Comprehensive Set of ITK Inhibitors. J. Biomol. Screen. 2007 ; 12: 70-83
27. Klink T. A., Kleman-Leyer K. M., Kopp A., Westermeyer T. A., Lowery R. G.. Evaluating PI3 Kinase Isoforms Using Transcreener ADP Assays. J. Biomol. Screen. 2008 ; 13: 476-485
28. Zhang J. H., Chung T. D., Oldenburg K. R.. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73
29. Ahmad S., Carter J. J., Scott J. E.. A Homogeneous Cell-Based Assay for Measurement of Endogenous Paraoxonase 1 Activity. Anal. Biochem. 2010 ; 400: 1-9
30. Davis M. I., Hunt J. P., Herrgard S., Ciceri P., Wodicka L. M., Pallares G., Hocker M., Treiber D. K., Zarrinkar P. P.. Comprehensive Analysis of Kinase Inhibitor Selectivity. Nat. Biotechnol. 2011 ; 29: 1046-1051